-
341
-
342
-
343
Association of intratumoral microbiome diversity with hepatocellular carcinoma prognosis
Published 2025-01-01Get full text
Article -
344
Cellular therapies in rheumatic and musculoskeletal diseases
Published 2025-06-01Get full text
Article -
345
Protocol to identify endogenous proximal proteins using biotinylation by antibody recognition
Published 2025-03-01Get full text
Article -
346
-
347
Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics
Published 2025-01-01Get full text
Article -
348
-
349
Investigation of IL-17A Serum Levels in Patients with Nonmelanoma Skin Cancer
Published 2021-01-01Get full text
Article -
350
The Multi‐Kinase Inhibitor GZD824 (Olverembatinib) Shows Pre‐Clinical Efficacy in Endometrial Cancer
Published 2025-01-01Get full text
Article -
351
-
352
-
353
Loss of YTHDC1 m6A reading function promotes invasiveness in urothelial carcinoma of the bladder
Published 2025-01-01Get full text
Article -
354
-
355
-
356
-
357
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carbo...
Published 2024-12-01“…ACTOv is open to National Health Service hospitals throughout the UK, recruitment is anticipated to take 36 months across 10 sites and will be managed by the Cancer Research UK and University College London Cancer Trials Centre.Ethics and dissemination The trial has been reviewed and received approval from the London—Dulwich Research Ethics Committee (REC). …”
Get full text
Article -
358
-
359
-
360